Eva Carro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5508433/publications.pdf

Version: 2024-02-01

108 papers	7,471 citations	50273 46 h-index	54911 84 g-index
114 all docs	114 docs citations	114 times ranked	8846 citing authors

#	Article	IF	Citations
1	Saliva is a Good Candidate to be the New Gold-Standard Sample for Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2022, , 1-5.	2.6	4
2	Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimerâ€™s Disease Patients. Frontiers in Immunology, 2022, 13, 878201.	4.8	5
3	Amyloid-Î² impairs mitochondrial dynamics and autophagy in Alzheimerâ€™s disease experimental models. Scientific Reports, 2022, 12, .	3.3	22
4	Differentially Aquaporin 5 Expression in Submandibular Glands and Cerebral Cortex in Alzheimerâ€™s Disease. Biomedicines, 2022, 10, 1645.	3.2	4
5	Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12173.	2.4	5
6	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie, 2021, 133, 19493-19503.	2.0	2
7	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie - International Edition, 2021, 60, 19344-19354.	13.8	9
8	Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging. Alzheimer's Research and Therapy, 2021, 13, 150.	6.2	11
9	Salivary Lactoferrin Expression in a Mouse Model of Alzheimerâ€™s Disease. Frontiers in Immunology, 2021, 12, 749468.	4.8	9
10	Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine, 2020, 57, 102834.	6.1	59
11	The Rhythmicity of Clock Genes is Disrupted in the Choroid Plexus of the APP/PS1 Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 795-806.	2.6	20
12	Decreased salivary lactoferrin levels are specific to Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042621.	0.8	1
13	Annexin A5 prevents amyloid-Î²-induced toxicity in choroid plexus: implication for Alzheimerâ€™s disease. Scientific Reports, 2020, 10, 9391.	3.3	18
14	Salivary lactoferrin as biomarker for Alzheimer's disease: Brainâ€immunity interactions. Alzheimer's and Dementia, 2020, 16, 1196-1204.	0.8	31
15	Endothelial-specific deficiency of megalin in the brain protects mice against high-fat diet challenge. Journal of Neuroinflammation, 2020, 17, 22.	7.2	8
16	Altered Redox State in Whole Blood Cells from Patients with Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 71, 153-163.	2.6	24
17	Lymphoproliferation Impairment and Oxidative Stress in Blood Cells from Early Parkinsonâ€™s Disease Patients. International Journal of Molecular Sciences, 2019, 20, 771.	4.1	24
18	Neurological Disorders in Central Spain, Second Survey: Feasibility Pilot Observational Study. JMIR Research Protocols, 2019, 8, e10941.	1.0	1

#	Article	IF	Citations
19	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 7327-7339.	4.0	24
20	Amyloid Î²-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. Alzheimer's Research and Therapy, 2018, 10, 24.	6.2	64
21	Platelet Proteomic Analysis Revealed Differential Pattern of Cytoskeletal- and Immune-Related Proteins at Early Stages of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 8815-8825.	4.0	11
22	Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 4885-4895.	4.0	21
23	The choroid plexus harbors a circadian oscillator modulated by estrogens. Chronobiology International, 2018, 35, 270-279.	2.0	28
24	Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimerâ€™s Disease. CNS Drugs, 2018, 32, 579-591.	5.9	4
25	Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinsonâ€™s Disease. Molecular Neurobiology, 2018, 55, 145-155.	4.0	95
26	Obesity and neuroinflammatory phenotype in mice lacking endothelial megalin. Journal of Neuroinflammation, 2017, 14, 26.	7.2	24
27	Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates. Scientific Reports, 2017, 7, 1666.	3.3	51
28	Mutations in valosin-containing protein (VCP) decrease ADP/ATP translocation across the mitochondrial membrane and impair energy metabolism in human neurons. Journal of Biological Chemistry, 2017, 292, 8907-8917.	3.4	27
29	Impairment of Several Immune Functions and Redox State in Blood Cells of Alzheimerâ€™s Disease Patients. Relevant Role of Neutrophils in Oxidative Stress. Frontiers in Immunology, 2017, 8, 1974.	4.8	51
30	Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 131-138.	2.4	93
31	Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease. Frontiers in Aging Neuroscience, 2016, 8, 163.	3.4	86
32	Potential Role of Aminoprocalcitonin in the Pathogenesis of Alzheimer Disease. American Journal of Pathology, 2016, 186, 2723-2735.	3.8	5
33	MAPT H1 Haplotype is Associated with Late-Onset Alzheimerâ€™s Disease Risk in APOE É›4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. Journal of Alzheimer's Disease, 2015, 49, 343-352.	2.6	32
34	Soluble Megalin is Reduced in Cerebrospinal Fluid Samples of Alzheimerâ€™s Disease Patients. Frontiers in Cellular Neuroscience, 2015, 9, 134.	3.7	16
35	High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1687-1699.	3.8	134
36	Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-ÎºB-dependent inflammation process in a mouse model of Parkinson's disease. Journal of Controlled Release, 2015, 203, 170-180.	9.9	48

#	Article	IF	Citations
37	PET-Florbetapir findings in primary cerebral amyloidoma. Journal of Neurology, 2015, 262, 1052-1054.	3.6	4
38	Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids and Surfaces B: Biointerfaces, 2015, 134, 304-313.	5.0	135
39	Expression of Regulatory Proteins in Choroid Plexus Changes in Early Stages of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2015, 74, 359-369.	1.7	17
40	Enhanced Hippocampal Neurogenesis in APP/Ps1 Mouse Model of Alzheimerâ€™s Disease After Implantation of VEGF-loaded PLGA Nanospheres. Current Alzheimer Research, 2015, 12, 932-940.	1.4	33
41	Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model. Neurobiology of Aging, 2014, 35, 1582-1595.	3.1	41
42	Choroid plexus implants rescue Alzheimerâ€™s disease-like pathologies by modulating amyloid-Î² degradation. Cellular and Molecular Life Sciences, 2014, 71, 2947-2955.	5.4	28
43	Leptin gene therapy attenuates neuronal damages evoked by amyloid-Î² and rescues memory deficits in APP/PS1 mice. Gene Therapy, 2014, 21, 298-308.	4.5	64
44	Alzheimer's Disease-Like Impaired Cognition in Endothelial-Specific Megalin-Null Mice. Journal of Alzheimer's Disease, 2014, 39, 711-717.	2.6	23
45	Neurogenic effects of Î²-amyloid in the choroid plexus epithelial cells in Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2013, 70, 2787-2797.	5.4	17
46	VEGF-releasing biodegradable nanospheres administered by craniotomy: A novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer's disease. Journal of Controlled Release, 2013, 170, 111-119.	9.9	56
47	Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2133-2145.	3.1	77
48	Intranasal Delivery of Plasma and Platelet Growth Factors Using PRGF-Endoret System Enhances Neurogenesis in a Mouse Model of Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e73118.	2.5	47
49	Systematic Evaluation of Magnetic Resonance Imaging and Spectroscopy Techniques for Imaging a Transgenic Model of Alzheimer's Disease (AÎ²PP/PS1). Journal of Alzheimer's Disease, 2012, 30, 337-353.	2.6	16
50	Encapsulated VEGF-Secreting Cells Enhance Proliferation of Neuronal Progenitors in the Hippocampus of AÎ²PP/Ps1 Mice. Journal of Alzheimer's Disease, 2012, 29, 187-200.	2.6	30
51	Pathological Alteration in the Choroid Plexus of Alzheimerâ€™s Disease: Implication for New Therapy Approaches. Frontiers in Pharmacology, 2012, 3, 75.	3.5	53
52	Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on AÎ² accumulation and cell death: Involvement in hippocampal neuronal loss in Alzheimer's disease. Neurobiology of Disease, 2012, 46, 682-691.	4.4	42
53	Altered cell cycleâ€related gene expression in brain and lymphocytes from a transgenic mouse model of Alzheimerâ€™s disease [amyloid precursor protein/presenilin 1 (PS1)]. European Journal of Neuroscience, 2012, 36, 2609-2618.	2.6	33
54	Prolonged oral cannabinoid administration prevents neuroinflammation, lowers Î²-amyloid levels and improves cognitive performance in Tg APP 2576 mice. Journal of Neuroinflammation, 2012, 9, 8.	7.2	196

#	Article	IF	Citations
55	IGF-I gene variability is associated with an increased risk for AD. Neurobiology of Aging, 2011, 32, 556.e3-556.e11.	3.1	36
56	PLA2G3, a Gene Involved in Oxidative Stress Induced Death, is Associated with Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1181-1187.	2.6	25
57	Leptin Induces Proliferation of Neuronal Progenitors and Neuroprotection in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 17-25.	2.6	97
58	The p75 neurotrophin receptor localization in blood-CSF barrier: expression in choroid plexus epithelium. BMC Neuroscience, 2011, 12, 39.	1.9	15
59	Hyperphagia and Central Mechanisms for Leptin Resistance during Pregnancy. Endocrinology, 2011, 152, 1355-1365.	2.8	69
60	A New Tacrineâ€“Melatonin Hybrid Reduces Amyloid Burden and Behavioral Deficits in a Mouse Model of Alzheimerâ€™s Disease. Neurotoxicity Research, 2010, 17, 421-431.	2.7	59
61	Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study. BMC Neurology, 2010, 10, 108.	1.8	146
62	A megalin polymorphism associated with promoter activity and Alzheimer's disease risk. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 895-902.	1.7	24
63	The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimerâ€™s disease. Biomaterials, 2010, 31, 5608-5618.	11.4	114
64	Gelsolin as therapeutic target in Alzheimer's disease. Expert Opinion on Therapeutic Targets, 2010, 14, 585-592.	3.4	23
65	Gelsolin Restores A<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î²</mml:mi></mml:math>-Induced Alterations in Choroid Plexus Epithelium. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	19
66	Risk of Incident Dementia in Drug-Untreated Arterial Hypertension: A Population-Based Study. Journal of Alzheimer's Disease, 2010, 22, 949-958.	2.6	28
67	Megalin interacts with APP and the intracellular adapter protein FE65 in neurons. Molecular and Cellular Neurosciences, 2010, 45, 306-315.	2.2	57
68	AÎ² accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. Neurobiology of Aging, 2010, 31, 1569-1581.	3.1	63
69	The effects of parkin suppression on the behaviour, amyloid processing, and cell survival in APP mutant transgenic mice. Experimental Neurology, 2010, 221, 54-67.	4.1	16
70	Therapeutic Approaches of Leptin in Alzheimers Disease. Recent Patents on CNS Drug Discovery, 2009, 4, 200-208.	0.9	20
71	Cytoplasmic gelsolin increases mitochondrial activity and reduces AÎ² burden in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2009, 36, 42-50.	4.4	64
72	Oxidative stress damage and oxidative stress responses in the choroid plexus in Alzheimerâ€™s disease. Acta Neuropathologica, 2009, 118, 497-504.	7.7	60

#	Article	IF	Citations
73	Induction of angiogenesis by implantation of encapsulated cells expressing vegf: A new therapy approach on Alzheimer's disease?. Journal of the Neurological Sciences, 2009, 283, 260.	0.6	0
74	Protection by gelsolin on amyloid-b-induced toxicity in the blood-CSF-brain barrier: Apoptotic pathways. Journal of the Neurological Sciences, 2009, 283, 299.	0.6	0
75	Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiology of Aging, 2008, 29, 902-912.	3.1	170
76	Western Style Diet Impairs Entrance of Blood-Borne Insulin-like Growth Factor-1 into the Brain. NeuroMolecular Medicine, 2007, 9, 324-330.	3.4	30
77	Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiology of Aging, 2006, 27, 1250-1257.	3.1	143
78	Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: New cues into the human disease?. Neurobiology of Aging, 2006, 27, 1618-1631.	3.1	129
79	Serum insulin-like growth factor I in brain function. Keio Journal of Medicine, 2006, 55, 59-63.	1.1	55
80	Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. Journal of NeuroVirology, 2005, 11, 281-291.	2.1	78
81	Insulin-like growth factor I treatment for cerebellar ataxia: Addressing a common pathway in the pathological cascade?. Brain Research Reviews, 2005, 50, 134-141.	9.0	39
82	Choroid Plexus Megalin Is Involved in Neuroprotection by Serum Insulin-Like Growth Factor I. Journal of Neuroscience, 2005, 25, 10884-10893.	3.6	190
83	Experimental Models for Understanding the Role of Insulin-like Growth Factor-I and Its Receptor During Development. , 2005, 567, 27-53.		5
84	Insulin-like growth factor I and AlzheimerÂ´s disease: therapeutic prospects?. Expert Review of Neurotherapeutics, 2004, 4, 79-86.	2.8	44
85	The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. European Journal of Pharmacology, 2004, 490, 127-133.	3.5	238
86	Role of insulin-like growth factor I signaling in neurodegenerative diseases. Journal of Molecular Medicine, 2004, 82, 156-162.	3.9	96
87	Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration. Biomaterials, 2004, 25, 707-714.	11.4	42
88	Role of serum insulin-like growth factor I in mammalian brain aging. Growth Hormone and IGF Research, 2004, 14, 39-43.	1.1	62
89	Brain Repair and Neuroprotection by Serum Insulin-Like Growth Factor I. Molecular Neurobiology, 2003, 27, 153-162.	4.0	106
90	Insulin-Like Growth Factor I Modifies Electrophysiological Properties of Rat Brain Stem Neurons. Journal of Neurophysiology, 2003, 89, 3008-3017.	1.8	63

#	Article	IF	Citations
91	Sedentary Life Impairs Self-Reparative Processes in the Brain: The Role of Serum Insulin-like Growth Factor-I. Reviews in the Neurosciences, 2002, 13, 365-74.	2.9	47
92	Serum insulin-like growth factor I regulates brain amyloid-Î² levels. Nature Medicine, 2002, 8, 1390-1397.	30.7	334
93	Circulating Insulin-Like Growth Factor I Mediates Exercise-Induced Increases in the Number of New Neurons in the Adult Hippocampus. Journal of Neuroscience, 2001, 21, 1628-1634.	3.6	889
94	Circulating Insulin-Like Growth Factor I Mediates the Protective Effects of Physical Exercise against Brain Insults of Different Etiology and Anatomy. Journal of Neuroscience, 2001, 21, 5678-5684.	3.6	527
95	Regulation of somatotroph cell function by the adipose tissue. International Journal of Obesity, 2000, 24, S100-S103.	3.4	25
96	Circulating Insulin-Like Growth Factor I Mediates Effects of Exercise on the Brain. Journal of Neuroscience, 2000, 20, 2926-2933.	3.6	645
97	Leptin increases in vivo GH responses to GHRH and GH-releasing peptide-6 in food-deprived rats. European Journal of Endocrinology, 2000, 142, 66-70.	3.7	26
98	Regulation of in vivo TSH secretion by leptin. Regulatory Peptides, 2000, 92, 25-29.	1.9	98
99	Role of Growth Hormone (GH)-Releasing Hormone and Somatostatin on Leptin-Induced GH Secretion. Neuroendocrinology, 1999, 69, 3-10.	2.5	81
100	Regulation of serum leptin levels by gonadal function in rats. European Journal of Endocrinology, 1999, 140, 468-473.	3.7	78
101	Regulation of hypothalamic somatostatin and growth hormone releasing hormone mRNA levels by inhibin. Molecular Brain Research, 1999, 66, 191-194.	2.3	3
102	Influence of Gonadal Function on GH Secretion. , 1999, , 243-248.		0
103	Inhibin Suppresses in vivo Growth Hormone Secretion. Neuroendocrinology, 1998, 68, 293-296.	2.5	5
104	Interaction between Leptin and Neuropeptide Y on in vivo Growth Hormone Secretion. Neuroendocrinology, 1998, 68, 187-191.	2.5	41
105	Influence of Endogenous Leptin Tone on the Estrous Cycle and Luteinizing Hormone Pulsatility in Female Rats. Neuroendocrinology, 1997, 66, 375-377.	2.5	142
106	Retinoic acid inhibits in vivo thyroid-stimulating hormone secretion. Life Sciences, 1997, 60, PL247-PL250.	4.3	23
107	Regulation of in Vivo Growth Hormone Secretion by Leptin. Endocrinology, 1997, 138, 2203-2203.	2.8	95
108	Acute ethanol administration in diestrus-2 in the rat on pulsatile prolactin and LH release. Pharmacology Biochemistry and Behavior, 1994, 49, 789-794.	2.9	3